Evaluating the efficacy of secondary transurethral resection of the bladder for high-grade Ta tumors
- PMID: 34983118
- PMCID: PMC8756150
- DOI: 10.4111/icu.20210314
Evaluating the efficacy of secondary transurethral resection of the bladder for high-grade Ta tumors
Abstract
Purpose: The need for secondary transurethral resection of the bladder (re-TURB) in patients with high-grade Ta tumors has not been assessed. This study aimed to compare the outcomes of patients with high-grade Ta tumors who did and did not undergo re-TURB.
Materials and methods: This study used data from the Seoul National University Prospectively Enrolled Registry for Urothelial Cancer-Transurethral Bladder Tumor Resection (SUPER-UC-TURB). Patients with high-grade Ta tumors who underwent TURB between March 2016 and December 2019 were included. Following the initial TURB, if the pathology results showed a tumor grade higher than high-grade Ta, re-TURB was performed according to the surgeon's recommendation. The recurrence-free survival rate was assessed by Kaplan-Meier analysis and Cox regression analysis between patients who did and did not undergo re-TURB.
Results: In total, 187 patients with high-grade Ta who underwent initial TURB were included, of whom 115 underwent re-TURB and 72 did not. Patients in the re-TURB group had a significantly higher 2-year recurrence-free survival rate than did those in the no re-TURB group (81.3% vs. 60.1%; p=0.005). Whether patients underwent re-TURB was a significant predictor of the risk of bladder cancer recurrence in both the univariate (HR, 0.52; 95% CI, 0.27-0.98; p=0.044) and multivariate (HR, 0.41; 95% CI, 0.19-0.97; p=0.041) analysis.
Conclusions: The risk for bladder cancer recurrence was increased, and the 2-year recurrence-free survival was significantly decreased, in patients with high-grade Ta tumors who did not undergo re-TURB. Thus, re-TURB is beneficial in patients with high-grade Ta bladder cancer.
Keywords: Recurrence; Survival rate; Urinary bladder neoplasms.
© The Korean Urological Association, 2022.
Conflict of interest statement
The authors have nothing to disclose.
Figures

Similar articles
-
Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well-selected patients?Urol Oncol. 2020 Mar;38(3):77.e1-77.e7. doi: 10.1016/j.urolonc.2019.08.010. Epub 2019 Sep 14. Urol Oncol. 2020. PMID: 31526650
-
Grading and staging of bladder carcinoma in transurethral resection specimens. Correlation with 105 matched cystectomy specimens.Am J Clin Pathol. 2000 Feb;113(2):275-9. doi: 10.1309/94B6-8VFB-MN9J-1NF5. Am J Clin Pathol. 2000. PMID: 10664630
-
Clinical determinants of recurrence in pTa bladder cancer following transurethral resection of bladder tumor.BMC Cancer. 2022 Jun 8;22(1):631. doi: 10.1186/s12885-022-09733-8. BMC Cancer. 2022. PMID: 35676678 Free PMC article.
-
Current concept of transurethral resection of bladder cancer: from re-transurethral resection of bladder cancer to en-bloc resection.Curr Opin Urol. 2018 Nov;28(6):591-597. doi: 10.1097/MOU.0000000000000542. Curr Opin Urol. 2018. PMID: 30102624 Review.
-
Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review.Eur Urol. 2018 Jun;73(6):925-933. doi: 10.1016/j.eururo.2018.02.014. Epub 2018 Mar 6. Eur Urol. 2018. PMID: 29523366
Cited by
-
Utility of restaging transurethral resection in patients with primary high-grade Ta bladder cancer.World J Urol. 2025 Jun 23;43(1):387. doi: 10.1007/s00345-025-05778-z. World J Urol. 2025. PMID: 40551001
-
IVC treatment between primary and second TURBT may improve the prognosis of high-risk NMIBC patients receiving BCG treatment.Sci Rep. 2025 Feb 10;15(1):4874. doi: 10.1038/s41598-025-89008-x. Sci Rep. 2025. PMID: 39930090 Free PMC article.
-
Intravesical chemotherapy in BCG waiting period may prolong time to recurrence for high-risk NMIBC patients.BMC Cancer. 2025 Feb 14;25(1):268. doi: 10.1186/s12885-025-13705-z. BMC Cancer. 2025. PMID: 39953419 Free PMC article.
-
Repeat TURBT in large volume high-grade non-invasive bladder cancer.Bladder Cancer. 2024 Dec 20;10(4):270-277. doi: 10.1177/23523735241303350. eCollection 2024 Dec. Bladder Cancer. 2024. PMID: 40035080 Free PMC article.
References
-
- International Agency for Research on Cancer (IARC) Estimated number of new cases in 2020, worldwide, both sexes, all ages [Internet] Lyon: IARC; 2021. [Cited 2021 Sep 6]. Available from: https://gco.iarc.fr/today/online-analysis-table?v=2020&mode=cancer&mode_... .
-
- Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71:96–108. - PubMed
-
- David KA, Mallin K, Milowsky MI, Ritchey J, Carroll PR, Nanus DM. Surveillance of urothelial carcinoma: stage and grade migration, 1993-2005 and survival trends, 1993-2000. Cancer. 2009;115:1435–1447. - PubMed
-
- Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19:666–675. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical